With this renewed partnership, Tigermed will deepen its reliance on the Medidata Platform to boost research efficiency and enhance trial compliance, ultimately facilitating greater access to novel therapies.

Shanghai, China, February 5, 2025 - Medidata, a pioneering provider of clinical trial solutions for the life sciences industry and a Dassault Systèmes brand, announced the extension of its 13-year strategic alliance with Tigermed, a leading integrated biopharmaceutical R&D service platform. This renewal paves the way for Tigermed to further integrate the Medidata Platform across all stages, from early trials to post-marketing surveillance, optimizing clinical research workflows, ensuring compliance, and accelerating the availability of new therapies to patients worldwide, including those in emerging markets.

Since 2011, the Medidata Platform has supported Tigermed in successfully conducting over 300 clinical studies across diverse therapeutic areas, including oncology, vaccines, endocrine diseases, and cardiovascular diseases. Building on their established and robust collaboration, Tigermed will continue to embed the Medidata Platform into its workflows, further augmenting trial efficiency through automated data collection, operational optimization, and other traditionally labor-intensive aspects of CRO services. This will foster enhanced connectivity among patients, research centers, and sponsors, thereby accelerating the launch of novel therapies.

"By partnering with Medidata, our clients can make data-driven decisions, accelerating the attainment of new milestones," said Mr. Hao Wu, Executive Director and Co-President of Tigermed. "We have a rich history of cooperation with Medidata and are thrilled to continue this partnership and embark on a new chapter. We anticipate leveraging more of Medidata's cutting-edge technologies, such as Medidata AI, to shape the future of global clinical trials."

"Tigermed's evolution embodies the transformation and advancement within the CRO industry, as they embrace innovation and relentlessly drive the quality and efficiency of clinical trials," said Mr. Edwin Ng, Senior Vice President and General Manager of Asia Pacific at Medidata. "Looking ahead, both parties will continue to collaborate, jointly exploring and breaking through the boundaries of clinical trial management, enhancing the research experience, and ultimately aiding sponsors in achieving superior R&D outcomes that benefit patients."

About Medidata

Medidata is revolutionizing clinical trials with innovative digital solutions, enabling smarter therapies, and improving human health. Over its 25-year history, Medidata has supported over 35,000 trials involving more than 10 million patients. Through disruptive technological innovations, Medidata offers the industry unparalleled experience and expertise, analytics-driven trial insights, and the world's largest historical dataset of clinical trial patients. Over 1 million registered users at approximately 2,300 clients globally trust Medidata's seamlessly integrated end-to-end platform to enhance patient experiences, accelerate clinical breakthroughs, and expedite the market launch of innovative therapies. Medidata, a Dassault Systèmes brand (Euronext Paris: #14003TT8, DSY.PA), is headquartered in New York City and is recognized as an industry leader by both Everest Group, a global consulting and research firm, and IDC, a leading global provider of market intelligence and advisory services for the information technology industry. In China, Medidata officially entered the market in 2015 and established offices in Beijing and Shanghai to offer immediate and professional services to Chinese clients. For more information, please visit Medidata's official website at www.medidata.com/cn and follow Medidata's official WeChat account.

About Dassault Systèmes

Dassault Systèmes aims to catalyze human progress. Since 1981, Dassault Systèmes has been driving the development of the virtual world to improve the real world, benefiting consumers, patients, and citizens. Through the 3DEXPERIENCE platform, Dassault Systèmes provides solutions for collaboration, imagination, and sustainable innovation to 350,000 customers of all sizes across various industries worldwide, jointly driving profound societal changes. For more information, please visit: www.3ds.com

About Tigermed

Tigermed (stock code: 300347.SZ/3347.HK) is a leading integrated biopharmaceutical R&D service platform offering innovative full-cycle R&D solutions for the global pharmaceutical and medical device industries. Through a comprehensive service system and top-tier quality standards, Tigermed helps the biopharmaceutical industry enhance R&D efficiency, mitigate R&D risks, ensure high-quality project delivery, accelerate the commercialization of pharmaceutical products, and fulfill its commitments to the industry and patients. Additionally, Tigermed builds an innovation ecosystem that empowers the entire industry chain through over 100 subsidiaries spanning various fields, driving innovation and development in the healthcare industry. As a global R&D platform, Tigermed operates over 180 offices and branches worldwide, with a professional team of over 10,000 people across dozens of countries on five continents. Tigermed is dedicated to addressing the most challenging global health issues, meeting unmet medical needs, creating social value, and benefiting human health.